var data={"title":"Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5651?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information\" class=\"drug drug_general\">see &quot;Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Drug information&quot;</a> and <a href=\"topic.htm?path=prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-patient-drug-information\" class=\"drug drug_patient\">see &quot;Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10514505\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Thromboembolic events:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Thromboembolic events have been reported during postmarketing surveillance following infusion of anti-inhibitor coagulant complex, particularly following the administration of high doses and/or in patients with thrombotic risk factors. Monitor patients receiving anti-inhibitor coagulant complex for signs and symptoms of thromboembolic events.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135834\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>FEIBA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135835\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>FEIBA NF</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2528322\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihemophilic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Blood Product Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2528329\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information\" class=\"drug drug_general\">see &quot;Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Anti-inhibitor coagulant complex (Human) contains mainly nonactivated therapeutic levels of factors II, IX, and X and mainly activated factor VII.   Dosage is expressed in units of factor VIII inhibitor bypassing activity and is dependent upon the severity and location of bleeding, type and level of inhibitors, and whether the patient has a history of an anamnestic increase in antihemophilic inhibitor levels following use of preparations containing antihemophilic factor. Maximum dose should only be exceeded if bleeding severity warrants; monitor closely for DIC, coronary ischemia and/or signs and symptoms of other thromboembolic events. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Control and prevention of bleeding episodes:</b> Infants, Children, and Adolescents: <b>Note:</b> Dosage will vary with the bleeding site and severity.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Joint hemorrhage:</i> IV:  50 to 100 units/kg/dose every 12 hours until pain and acute disabilities are improved; maximum daily dose: 200 units/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mucous membrane bleeding:</i> IV:  50 to 100 units/kg/dose every 6 hours for at least one day or until bleeding is resolved; maximum daily dose: 200 units/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Soft tissue hemorrhage (eg, retroperitoneal bleeding):</i> IV: 100 units/kg/dose every 12 hours until resolution of bleed; maximum daily dose: 200 units/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Other severe hemorrhages (eg, CNS bleeds):</i> IV: 100 units/kg/dose every 6 to 12 hours until resolution of bleed; maximum daily dose: 200 units/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Perioperative management:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Preoperative:</i> IV: 50 to 100 units/kg (single dose) administered immediately prior to surgery</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Postoperative:</i> IV: 50 to 100 units/kg/dose every 6 to 12 hours until resolution of bleed and healing is achieved; maximum daily dose: 200 units/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Routine prophylaxis:</b> Infants, Children, and Adolescents: IV: 85 units/kg/dose every other day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Control and prevention of bleeding episodes: Note:</b> dosage may vary with the bleeding site and severity.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Joint hemorrhage:</i> IV:  50 to 100 units/kg/dose every 12 hours until pain and acute disabilities are improved; maximum daily dose: 200 units/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mucous membrane bleeding:</i> IV: 50 to 100 units/kg/dose every 6 hours for at least 1 day or until bleeding is resolved; maximum daily dose: 200 units/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Soft tissue hemorrhage (eg, retroperitoneal bleed):</i> IV: 100 units/kg/dose every 12 hours until resolution of bleed; maximum daily dose: 200 units/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Other severe hemorrhage (eg, intracranial hemorrhage):</i> IV: 100 units/kg/dose every 6 to 12 hours until resolution of bleed; maximum daily dose: 200 units/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Perioperative management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Preoperative:</i> IV:  50 to 100 units/kg (single dose) administered immediately prior to surgery</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Postoperative:</i> IV: 50 to 100 units/kg/dose every 6 to 12 hours until resolution of bleed and healing is achieved; maximum daily dose: 200 units/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Routine prophylaxis:</b> IV: 85 units/kg/dose every other day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135824\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FEIBA: 500 units (1 ea); 1000 units (1 ea); 2500 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135810\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573580\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information\" class=\"drug drug_general\">see &quot;Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FEIBA strengths expressed in terms of Factor VIII inhibitor bypassing activity with nominal strength values. Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2528330\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV injection or infusion only; maximum infusion rate: 2 units/kg/minute. Following reconstitution, complete infusion use within 3 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135831\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at &le;25&deg;C (77&deg;F); store in the original package to protect from light. Do <b>not</b> freeze. Following reconstitution, do not refrigerate and administer within 3 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2528323\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Control and prevention of bleeding episodes, perioperative bleeding management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B with inhibitors [All indications: FDA approved in infants (&gt;28 days of life), children, adolescents, and adults] </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> Not indicated for the treatment of bleeding resulting from coagulation factor deficiencies in the absence of inhibitors to factor VIII or factor IX.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135855\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cerebrovascular accident (embolic/thrombotic stroke), chest discomfort, chest pain, decreased blood pressure, flushing, hypertension, hypotension, myocardial infarction, pulmonary embolism, tachycardia, thromboembolism, thrombosis (arterial thrombosis, venous thrombosis)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Chills, dizziness, drowsiness, headache, hypoesthesia (including facial), malaise, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Pruritus, skin rash, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal distress, diarrhea, dysgeusia, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Disseminated intravascular coagulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Angioedema, hypersensitivity reaction (including anaphylaxis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immunologic: Antibody development (anamnestic response)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bronchospasm, cough, dyspnea, wheezing </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135828\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known anaphylactic or severe hypersensitivity to anti-inhibitor coagulant complex or any component of the formulation, including factors of the kinin generating system; disseminated intravascular coagulation (DIC); acute thrombosis or embolism (including myocardial infarction)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135813\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity and allergic reactions (including severe and systemic reactions [eg, anaphylaxis with urticaria and angioedema, bronchospasm, circulatory shock]) have been observed following administration. Discontinue immediately with signs/symptoms of severe hypersensitivity reactions and provide appropriate supportive care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Infusion reactions (eg, chills, pyrexia, hypertension) have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: <b>[US Boxed Warning]: Thromboembolic events (including venous thrombosis, pulmonary embolism, MI, and stroke) have been reported following administration of anti-inhibitor coagulant complex, particularly with administration of high doses and/or in patients with thrombotic risk factors. Monitor patients receiving anti-inhibitor coagulant complex for signs and symptoms of thromboembolic events,</b> especially if more than 200 units/kg/day is administered. Use with caution in patients with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush injury, septicemia, or concomitant treatment with factor VIIa. Weigh the potential benefit of treatment against the potential risk of these thromboembolic events. Monitor patients receiving &gt;100 units/kg for the development of DIC, acute coronary ischemia, and signs/symptoms of other thromboembolic events. If clinical signs/symptoms occur, discontinue use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Factor VIII: Product contains minute amounts of factor VIII which may cause an anamnestic response; anamnestic rises were not associated with reduced efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents that could transmit disease. During the manufacturing process, screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer and/or to FDA MedWatch. Patients with signs/symptoms of infection (eg, fever, chills, drowsiness) should be encouraged to consult health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to factor VIII or factor IX. Use of antifibrinolytics within ~6 to 12 hours after the administration of anti-inhibitor coagulant complex is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298760\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869874\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12912&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antifibrinolytic Agents: May enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Emicizumab-kxwh: May enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135820\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869871\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Animal reproduction studies have not been conducted. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2528331\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for control of bleeding; signs and symptoms of DIC (blood pressure changes, pulse rate changes, chest pain/cough, fibrinogen, platelet count, fibrin-fibrinogen degradation products, significantly-prolonged thrombin time, PT, or partial thromboplastin time), acute coronary ischemia and other thromboembolic events; hemoglobin and hematocrit; hypotension; have epinephrine ready to treat hypersensitivity reactions. <b>Note:</b> Tests used to monitor hemostatic efficacy, such as aPTT and TEG, are <b>not</b> useful for monitoring responses with anti-inhibitor coagulant complex (Hoffman 2012). Dosing to normalize these values may result in DIC. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23682864\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Multiple interactions of the components in anti-inhibitor coagulant complex restore the impaired thrombin generation of hemophilia patients with inhibitors. In vitro, anti-inhibitor coagulant complex shortens the activated partial thromboplastin time of plasma containing factor VIII inhibitor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20453114\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Peak thrombin generation: Within 15 to 30 minutes (Varadi 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 8 to 12 hours (based on thrombin generation) (Varadi 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 4 to 7 hours (based on thrombin generation) (Varadi 2003)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13335240\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">One unit of activity is defined as that amount of anti-inhibitor coagulant complex that shortens the activated partial thromboplastin time (aPTT) of a high titer factor VIII inhibitor reference plasma to 50% of the blank value.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13276659\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Autoplex (JP);</li>\n      <li>Autoplex-T (IL);</li>\n      <li>Feiba NF (JP);</li>\n      <li>Feiba Tim 4 (KR, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    FEIBA (anti-inhibitor coagulant complex [human]) [prescribing information]. Westlake Village, CA: Baxter Healthcare Corporation; November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. <i>J Thromb Haemost</i>. 2012;10(8):1478-1485.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/22632160/pubmed\" target=\"_blank\" id=\"22632160\">22632160</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    V&aacute;radi K, Negrier C, Berntorp E, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. <i>J Thromb Haemost</i>. 2003;1(11):2374-2380.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information/abstract-text/14629472 /pubmed\" target=\"_blank\" id=\"14629472 \">14629472 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12912 Version 82.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F10514505\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F135834\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F135835\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F2528322\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F2528329\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135824\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F135810\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25573580\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2528330\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F135831\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2528323\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135855\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135828\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135813\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298760\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2869874\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F135820\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2869871\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2528331\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F23682864\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F20453114\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F13335240\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F13276659\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12912|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information\" class=\"drug drug_general\">Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Drug information</a></li><li><a href=\"topic.htm?path=prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-patient-drug-information\" class=\"drug drug_patient\">Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Patient drug information</a></li></ul></div></div>","javascript":null}